FSMP-07. CYSTATHIONINE-Γ-LYASE DRIVES ANTIOXIDANT DEFENSE IN CYSTEINE-RESTRICTED IDH1 MUTANT ASTROCYTOMAS. (25th March 2021)

• Record Type: Journal Article
• Authors: Cano-Galiano, Andrés; Oudin, Anais; Fack, Fred; Allega, Maria-Francesca; Sumpton, David; Martinez-Garcia, Elena; Dittmar, Gunnar; Hau, Ann-Christin; Herold-Mende, Christel; Bjerkvig, Rolf; Meiser, Johannes; Tardito, Saverio; Niclou, Simone P
• Is Part Of: Neuro-oncology advances. Volume 3(2021)Supplement 1
• Page Start: i17
• Page End: i17
• Publication Date: 2021-03-25
• Subjects: 616.99481
• DOI: 10.1093/noajnl/vdab024.071
• Languages: English
• ISSNs: 2632-2498

Abstract

Abstract: Mutations in isocitrate dehydrogenase 1 or 2 ( IDH1/2 ) define glioma subtypes and are considered primary events in gliomagenesis, impacting tumor epigenetics and metabolism. IDH enzymes are crucial for the generation of reducing potential, yet the impact of the mutation on the cellular antioxidant system is not understood. Here, we investigate how glutathione (GSH) levels are maintained in IDH1 mutant gliomas, despite an altered NADPH/NADP balance. We find that IDH1 mutant astrocytomas specifically upregulate cystathionine γ-lyase (CSE), the enzyme responsible for cysteine production upstream of GSH biosynthesis. Genetic and chemical interference with CSE in patient-derived glioma cells carrying the endogenous IDH1 mutation, sensitized tumor cells to cysteine depletion, an effect not observed in IDH1 wild-type gliomas. This correlated with reduced GSH synthesis as shown by in vitro and in vivo serine tracing and led to delayed tumor growth in mice. Thus we show that IDH1 mutant astrocytic gliomas critically rely on NADPH-independent de novo GSH synthesis to maintain the antioxidant defense, which uncovers a novel metabolic vulnerability in this dismal disease.